Key result
Probiotics may limit ischemia/reperfusion injury and infarct size, showing potential for MI prevention and treatment.
Why the study?
The discovery of an enteric-cardioid axis offers a new route to examine the complex mechanism of myocardial infarction, with emerging evidence that the gut microbiota and probiotics influence disease development.
This review highlights the emerging role of the enteric-cardioid axis and the potential of probiotics to reduce ischemia/reperfusion injury and inflammation in acute myocardial infarction.
Hypothesis-generating for probiotics in MI; prospective trials needed before clinical consideration.
Myocardial infarction (MI) is associated with high rates of death and disability, and is the main cause of death due to cardiovascular disease and the most frequent cause of death in the developed world. Recent studies have shown that, in addition to traditional risk factors, such as hypertension, diabetes, hyperlipidemia, obesity, smoking and the environment, the gut microbiota plays an important role in MI development and progression. The discovery of an enteric-cardioid axis provides a new route to examine the complex mechanism of MI and has become a research hotspot in recent years. Experiments have suggested that probiotics decrease ischemia/reperfusion injury and inflammation, regulate lipid metabolism and decrease the myocardial infarction area. In this review, we discuss the relationship between probiotics and MI as well as potential underlying mechanisms, to provide new ideas for the prevention and treatment of MI.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2022) conducted a review in Acute Myocardial Infarction. Probiotics was evaluated. Probiotics may decrease ischemia/reperfusion injury and inflammation, regulate lipid metabolism, and decrease myocardial infarction area, offering potential for MI prevention and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: